Teva Pharmaceutical Industries Limited TEVA and Xenon Pharmaceuticals Inc. XENE announced the enrolment of the first patient in a phase IIb study on their pain management candidate, TV-45070 (4% and 8% w/w ointment). The candidate is being developed for the treatment of patients suffering from postherpetic neuralgia (PHN).
TV-45070 is a small molecule inhibitor of the sodium channel Nav1.7 and other sodium channels found in the pain-sensing peripheral nervous system being developed for the treatment of patients with various pain-related disorders including neuropathic and osteoarthritis pain.
The randomized, double-blind, placebo controlled, multi-site phase IIb study will evaluate the safety and efficacy of topically applied TV-45070 ointment compared to placebo.
We remind investors that Teva gained exclusive global rights to TV-45070 from Xenon Pharmaceuticals under a collaborative development and license agreement entered into in Dec 2012.
We are encouraged by Teva’s progress with TV-45070. According to the press release issued by Teva, PNH is estimated to affect about 20% of people suffering from herpes zoster (shingles) while 40% to 50% of PHN patients fail to respond to treatment.
Currently prescribed treatments for PHN include Acorda Therapeutics’ ACOR Qutenza.
Meanwhile, Teva is conducting a 300-patient, randomized phase IIb study on TV-45070 for the treatment of patients suffering from osteoarthritis of the knee. Data from the study is expected in the third quarter of 2015.
Teva currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Akorn, Inc. AKRX and Acorda. Both hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment